{
    "clinical_study": {
        "@rank": "111110", 
        "acronym": "LCD18K", 
        "arm_group": [
            {
                "arm_group_label": "Levodopa Carbidopa 100/25 tablets Test 1", 
                "arm_group_type": "Active Comparator", 
                "description": "single oral dose of levodopa carbidopa immediate release tablets"
            }, 
            {
                "arm_group_label": "Levodopa Carbidopa 100/25 tablets Ref. 1", 
                "arm_group_type": "Active Comparator", 
                "description": "single oral dose of levodopa carbidopa immediate release tablets"
            }, 
            {
                "arm_group_label": "Levodopa Carbidopa 100/25 tablets Test 2", 
                "arm_group_type": "Active Comparator", 
                "description": "single oral dose of levodopa carbidopa immediate release tablets"
            }, 
            {
                "arm_group_label": "Levodopa Carbidopa 100/25 tablets Ref. 2", 
                "arm_group_type": "Active Comparator", 
                "description": "single oral dose of levodopa carbidopa immediate release tablets"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is carried-out to describe and compare the plasma pharmacokinetics of levodopa and\n      carbidopa after oral single-dose administration of 100 mg levodopa plus 25 mg carbidopa by\n      means two fixed combination products (test: Isicom\u00ae 100/25 mg; reference: Nacom\u00ae 100/25 mg).\n\n      Additionally, to describe and compare the safety and tolerability of the two investigational\n      treatments administered to healthy subjects."
        }, 
        "brief_title": "Pharmacokinetic Study With Levodopa-carbidopa Fixed-dose Products in Healthy Subjects After Oral Administration", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Fasted State", 
        "detailed_description": {
            "textblock": "Isicom\u00ae 100/25 mg and Sinemet\u00ae (Trade name in Germany: Nacom\u00ae) 100/25 mg  are authorised\n      fixed-combination products containing 100 mg levodopa plus 25 mg carbidopa. These two\n      formulations were tested for bioequivalence in 1997 (DESITIN trial \u2116 LCD-010/K); based on\n      the regulatory provisions in place at that time (CPMP/EWP/QWP/1401/98), the two formulations\n      could be accepted to be bioequivalent.\n\n      The present study is proposed to be conducted in order to verify and confirm the\n      bioequivalence of Isicom\u00ae 100/25 mg (test formulation) and Nacom\u00ae 100/25 mg (reference\n      formulation) in agreement with the pertinent regulatory guidance that came in place 2010\n      (CHMP Guideline On The Investigation Of Bioequivalence - CPMP/EWP/QWP/1401/98- Rev. 1/ Corr\n      - Jan.2010)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females (females of non-childbearing potential or of childbearing potential\n             while taking medically appropriate contraception)\n\n          -  Race: Caucasian\n\n          -  Age: 18 to 45 years\n\n          -  Body weight: 50   100 kg\n\n          -  Body Mass Index:  18   26 kg.m-2\n\n          -  Healthy based on the screening examination\n\n          -  Willing and able to provide informed consent\n\n        Exclusion Criteria:\n\n          -  Previous participation in this trial or participant in any other trial during the\n             last 90 days\n\n          -  Donation of blood or plasma during the last 90 days or a history of blood loss\n             exceeding 300 mL within the last 3 months\n\n          -  History of any clinically relevant allergy including hypersensitivity to levodopa or\n             carbi-dopa and related excipients\n\n          -  Presence of any acute or chronic infection\n\n          -  Presence or history of any relevant co-morbidity\n\n          -  Resting systolic blood pressure > 160 or < 90 mmHg, diastolic blood pressure > 95 or\n             < 50 mmHg\n\n          -  Clinically relevant ECG-abnormalities, in particular prolonged QTc(F) of > 450 msec\n             in males and > 460 msec in females\n\n          -  Presence of any relevant abnormality in the laboratory safety tests, especially low\n             haemo-globin (< 120 g/L in females and (< 136 g/L in males) and increased liver\n             enzymes (2 times the upper limit of the normal range)\n\n          -  Positive serology for HBsAg or anti HCV\n\n          -  Positive HIV test\n\n          -  Positive alcohol or urine drug test at screening\n\n          -  Regular use of any prescription medicine (except for contraceptives) or\n             over-the-counter product, herbal product, hormone supplement, etc. in the 30 days\n             prior to the Screening visit\n\n          -  History of alcohol and/or drug abuse and/or daily use of > 30 g alcohol\n\n          -  Smoking more than 10 cigarettes/day or equivalent of other tobacco products\n\n          -  Suspicion or evidence that the subject is not trustworthy and reliable\n\n          -  Suspicion or evidence that the subject is not able to make a free consent or to\n             understand the information in this regard.\n\n          -  Positive pregnancy test\n\n          -  Lactating\n\n          -  Female subjects of child-bearing potential not using appropriate contraception in the\n             3 weeks prior to enrolment until two weeks after the last dose of the trial\n             medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02116465", 
            "org_study_id": "LCD-018/K", 
            "secondary_id": "2013-003175-35"
        }, 
        "intervention": {
            "arm_group_label": [
                "Levodopa Carbidopa 100/25 tablets Test 1", 
                "Levodopa Carbidopa 100/25 tablets Ref. 1", 
                "Levodopa Carbidopa 100/25 tablets Test 2", 
                "Levodopa Carbidopa 100/25 tablets Ref. 2"
            ], 
            "description": "oral administration", 
            "intervention_name": "Levodopa Carbidopa immediate release tablets", 
            "intervention_type": "Drug", 
            "other_name": [
                "isicom 100/25 mg", 
                "Nacom 100/25 mg"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Carbidopa", 
                "Levodopa", 
                "Carbidopa, levodopa drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sofia", 
                    "country": "Bulgaria", 
                    "zip": "1527"
                }, 
                "name": "Department of Clinical Pharmacology"
            }
        }, 
        "location_countries": {
            "country": "Bulgaria"
        }, 
        "number_of_arms": "4", 
        "official_title": "Open-label, Two-treatment, 4-period Replicated Crossover Study in Healthy Subjects to Investigate the Plasma Pharmacokinetics of Levodopa and Carbidopa After Oral Administration of Single Doses of Two Fixed-dose Combination Products", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Bulgaria: Bulgarian Drug Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Cmax (maximal plasma concentration), AUC (area under the curve)", 
            "measure": "Cmax and AUC(0-tz) of levodopa and carbidopa", 
            "safety_issue": "No", 
            "time_frame": "12 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02116465"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Desitin Arzneimittel GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Desitin Arzneimittel GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}